A simple and sensitive bioanalytical high-performance liquid chromatographic method with ultraviolet detection was developed and validated for the quantification of febuxostat (FEB) in human plasma. Ketoprofen was used as an internal standard. The analytes were extracted from human plasma samples by precipitation with acetonitrile. The reconstituted samples were chromatographed on C18 Bondapack 10 µm, 250 × 4.6 mm, Waters Column (Ireland) by using a mixture of acetonitrile and 0.5% aqueous phosphoric acid (pH 3) (52 : 48, v/v) as the mobile phase. The chromatographic separation was isocratically performed at room temperature at a flow rate of 1.0 mL/min with UV detection at 315 nm. The method exhibited a linear dynamic range over 0.05-5.00 µg/mL FEB in human plasma. The lower limit of quantification was 0.05 µg/mL. The results of the intra-and interday precision and accuracy studies were within the acceptable limits. The validated method was successfully applied for the determination of FEB in human plasma samples for application in bioequivalence studies.
Introduction
Febuxostat (FEB; Figure 1 ), designated chemically as [2-(3-cyano-4-isobutoxy phenyl)-4-methyl-1,3-thiazole-5-carboxylic acid], is classified as a xanthine oxidase inhibitor that is used in the treatment of hyperuricemia and chronic gout (1) . FEB is a nonpurine selective inhibitor of xanthine oxidase. It works noncompetitively by blocking the molybdenum protein center that is the active site on xanthine oxidase. Xanthine oxidase is needed to successively oxidize both hypoxanthine and xanthine to uric acid. Hence, FEB inhibits xanthine oxidase, thereby reducing the production of uric acid. FEB inhibits both oxidized and reduced form of xanthine oxidase, so it cannot be easily displaced from the molybdenum protein site. FEB was found to be superior to allopurinol in reducing the serum uric acid levels (2) (3) (4) (5) (6) . FEB received marketing approval by the European Medicines Agency on 21 April 2008 (2) and was approved by the US Food and Drug Administration on 16 February 2009 (3) . FEB is recommended for people who are intolerant of allopurinol (4) . Ketoprofen (internal standard, IS; Figure 1 ), designated chemically as R,S-2-(3-benzoylphenyl) propionic acid, was used as an internal standard.
FEB has been determined in bulk and pharmaceutical dosage forms by reversed-phase HPLC (7) (8) (9) (10) (11) (12) and spectrophotometric methods (13) (14) (15) . However, few methods were reported for the determination of FEB in biological matrices using HPLC either with UV detection (16) or with fluorescence detection (17) (18) (19) or LC-MS-MS (20) (21) (22) (23) (24) .
Bioequivalence and bioavailability studies require simple, highthroughput extraction and analytical methods for drugs in human plasma to save time and effort. In the present study, a simple, reliable, selective and rapid validated HPLC-UV method has been proposed for the determination of FEB in human plasma in order to be used frequently in bioequivalence and bioavailability studies. The bioequivalence pharmacokinetics results obtained from the application of the suggested method will be discussed in another paper.
acid, acetonitrile and methanol HPLC grade were purchased from Sigma-Aldrich Co., Germany. Bi-distilled water was produced inhouse (Aquatron Water Still A4000D, UK), and membrane filters (0.22 µm) from Chrom-Tech (UK) were used. All other solvents used were of analytical grade. The human plasma was obtained from VACSERA (Cairo, Egypt).
For application to a bioequivalence study, ADENURIC ® 80 mg film-coated tablets, labeled to contain 80 mg FEB per each tablet, manufactured by Menarini International O.L.S.A., Luxembourg, was supplied as a reference product.
Equipment
The analysis was performed using the Schimadzu HPLC system throughout, comprising isocratic pump (model LC-10 AS, Shimadzu, Japan), ultraviolet variable wavelength detector (Model SPD-10 A, Shimadzu, Japan), autosampler (SIL-20A, Shimadzu, Japan), centrifuge (Sigma, Germany), vortex mixer (Stuart, England), ultrasonic processor (Elma, Germany) and vacuum concentrator (Ependorff, Germany). Data acquisition and data integration were done using the Lab solution software.
Chromatographic conditions
Separations were performed on a reversed-phase column (Bondapack C18, 10 μm, 250 × 4.6 mm, Waters, Ireland) using a mixture of acetonitrile and 0.5% aqueous phosphoric acid ( pH 3) (52 : 48, v/v) as the mobile phase. The mobile phase was prepared by dissolving 0.5 g of phosphoric acid in each 100 mL of water, then pH was adjusted to 3 and acetonitrile was finally mixed. The chromatographic separation was isocratically performed at room temperature at a flow rate of 1.0 mL/min with UV detection at 315 nm.
Preparation of calibration and quality control standard solutions
Standard stock solutions of FEB (100 µg/mL) and the IS (100 µg/mL) were separately prepared in methanol. Secondary standard solutions (10 µg/mL) for calibration and quality control (QC) samples were prepared by appropriate dilution in methanol. The IS working solution (10 µg/ml) was prepared by diluting its stock solution in methanol. Eight different working solutions of FEB (WS1-WS8) were prepared by appropriate dilutions from its stock solution. Calibration standards and QC samples were prepared and stored at a nominal temperature of −20°C. Calibration standards were codified from CS1 to CS8 and QC samples were codified as QCL, QCM and QCH for the low, medium and high concentrations, respectively.
Before using the human plasma, it was chromatographed to determine possible interference with FEB or internal standard. No significant interferences were observed in the lots of human plasma used for the preparation of calibration standards and QC samples.
General procedure for plasma samples
Plasma sample (500 µL) was pipetted into a 15-mL glass tube, vortexed with 100 µL of internal standard and 750 µL of acetonitrile for 30 s. The solution was then centrifuged for 10 min at 1792 g and then 10 µL of the supernatant was injected on the column for analysis.
Under the conditions described, the retention time of FEB and IS was 6.70 and 5.30 min, respectively.
Bioanalytical method validation
The validation of the above method was carried out according to the US FDA guidelines (25) . The parameters determined were selectivity, matrix effect, linearity, lower limit of quantification (LLOQ), precision, accuracy, recovery, stability and dilution integrity.
Selectivity
Plasma samples (six blanks) were chromatographed to check for endogenous components, which might interfere with FEB or IS in the lots of human plasma used for the preparation of calibration standards and QC samples. On the day of the study, all subjects had a blank plasma sample collected before drug administration to insure the absence of any interference at the analyte and IS retention time.
Linearity and range
Six calibration curves each consisting of a blank, zero sample and eight calibration standards were prepared in human plasma and chromatographed. The concentrations of calibration standards cover the range of 0.05-5.00 µg/mL. The calibration curves were generated using the analyte-to-IS peak area ratios by least-squares linear regression on consecutive days. The acceptance criterion for a calibration curve was a correlation coefficient (r) of 0.99 or better, and each backcalculated standard concentration must be within 15% deviation from the nominal value except at the LLOQ, for which the maximum acceptable deviation was set at 20%. At least 67% of non-zero standards were required to meet the above criteria, including LLOQ and upper limit of quantification.
Lower limit of quantification LLOQ was established as the lowest calibration standard with an accuracy of 80-120% and precision of <20%. The signal-to-noise ratio of the LLOQ signal should not be <10.
Precision and accuracy
Precision and accuracy of the method were assessed by analyzing QC samples at the concentrations mentioned above along with a calibration curve. To evaluate intraday precision and accuracy, six samples of each QC concentration were processed and analyzed on the same day. To evaluate interday precision and accuracy, six samples of each QC concentration were analyzed per day on 3 different days. Percent accuracy was evaluated as: [(mean found concentration)/(nominal concentration)] × 100. Precision was expressed as the %CV.
Recovery
The recovery of FEB from the extraction procedure was determined by comparing the peak area of FEB (three concentrations, each of low, medium and high QCs) in spiked plasma samples that were exposed to the whole extraction procedure ( pre-extraction samples) with that of FEB in samples spiked at the end of the extraction procedure ( postextraction samples).
Stability of the analytes
The stability of the analytes in human plasma was investigated in four ways, in order to characterize each operation during the process of analysis of bioequivalence samples: short-term stability at room temperature, post-preparative stability in the autosampler, freeze-thaw stability and long-term stability at −85°C. For all stability studies, the QC samples, QCL, QCM and QCH were used. Three replicates of those QC samples were freshly processed with a calibration curve and analyzed in a single run to serve as time 0 (comparison or fresh samples).
Short-term storage and post-preparative stability. Two sets of three replicates of each QC samples were prepared, immediately processed and stored in the thermostated autosampler (25°C) at room temperature (stability samples). One set of samples was injected after 6 h (short-term storage) and the other set of samples was injected after 12 h ( post-preparative stability). For each set, a calibration curve was freshly processed and analyzed with all stability samples in a single run. The stability samples were compared with the fresh ones at equivalent concentration.
Freeze and thaw stability. The stability of FEB was assessed in plasma samples subjected to three freeze (−20°C)-thaw (25°C) cycles during 24 h. Three replicates of each QC sample were prepared and subjected to three cycles of freeze-thaw operations in 3 consecutive days. After the third cycle, the samples were analyzed against calibration curve of the day. The mean concentration calculated for the samples subjected to the cycles and the fresh ones at equivalent concentration were compared.
Long-term stability. Three replicates of each QC sample were subjected to freeze storage (−85°C) during the entire period covered by the bioequivalence study, that is, from the first day of subjects sample collection up to the last day of sample analysis (50 days). Storage stability was defined, comparing sample concentration with the mean values obtained at first-day analysis. The values were calculated against a calibration curve of the day and the mean values for the stored samples and the fresh ones at equivalent concentration were compared.
The requirement for stable analytes was that the % recovery of the tested stability samples under various conditions related to the fresh samples has to be 100 ± 15%.
Results

Method validation
Selectivity No significant interferences were observed in the lots of human plasma used for the preparation of calibration standards and QC samples. The selectivity of the method was examined by analyzing blank human plasma extract, a blank plasma sample spiked with IS only (Figure 2 ) and a blank plasma sample spiked with both FEB and IS ( Figure 3 ). As shown in Figure 3 , no significant direct interference in the blank plasma traces was observed from endogenous substances in drug-free human plasma at the retention time of the analyte and IS. The retention times of FEB and the IS were ∼6.7 and 5.3 min, respectively. The overall run time was 7.5 min.
Linearity of calibration curve
The linearity was evaluated by calculating the linear regression of the peak area ratios versus concentrations (Table I) . Calibration curves were found to be consistently accurate and precise over the calibration range of 0.05-5.00 µg/mL. The mean correlation coefficient (r) was equal to 0.9981. Back-calculations of calibration standard samples (CS1-CS8) were made from the calibration curves to determine analyte concentrations of each calibration standard. Data are presented in Table II .
Intraday accuracy and precision
The intraday accuracy and precision evaluations were assessed by repeated analysis of human plasma samples containing different concentrations of FEB on separate occasions in the same day. A single run consisted of a calibration curve and six runs of low (QCL), medium (QCM) and high (QCH) QC samples, and the results are presented in Table III .
Interday accuracy and precision
Interday accuracy and precision evaluations were performed by analyzing three sets of QCL, QCM and QCH QC samples of FEB in human plasma. One set was extracted and analyzed on 1 day (Day I). The other two sets were kept frozen, thawed, extracted and analyzed on a next day (Day II) for the second set, and third day (Day III) for the last set. Results are presented in Table III .
Recovery
The recovery of FEB was evaluated by comparing mean analyte responses of two processed samples of low (QCL), medium (QCM) and high (QCH) QC samples to mean analyte responses of the same concentrations with spiked samples in previously extracted blank plasma. As per the acceptance criteria, the recovery of the analytes does not need to be 100%, but the extent of recovery of an analyte should be consistent, precise and reproducible. Mean recovery values were 77.56, 78.02 and 79.02% at low, medium and high QC levels, respectively.
Lower limit of quantification LLOQ was found to be 0.05 µg/mL with a coefficient of variation and a percentage of nominal concentration values of 12.41 and 101.88%, respectively. LLOQ must demonstrate a signal-to-noise ratio ≥ 5. LLOQ of FEB is 0.05 µg/mL with a signal-to-noise ratio of 10.83.
Dilution integrity
If samples require dilution before analysis, the dilution procedure should be tested to confirm the absence of any impact on the measured concentration of the analyte. Dilution integrity should be evaluated by the replicate analysis of at least five times per dilution factor after diluting a sample with blank matrix to bring the analyte concentration within the calibration range. Three replicates of the QCH were diluted five times in human plasma prior to sample processing and analysis. The results are presented in Table IV .
System suitability test
The system suitability parameters of the presented chromatographic method are calculated as illustrated in Table V . 
Stability
All the stability studies of FEB in plasma were conducted at the QCL, QCM and QCH levels with three determinations for each under different storage conditions. The % recovery of all stability samples was within 100 ± 15% in all stability tests of FEB in plasma. No effect on the quantification was observed for plasma samples kept at room temperature for 6 h on benchtop and 12 h in an autosampler. There was also no significant degradation when samples of FEB in plasma were subjected to three freeze (−20°C) and thaw (25°C) cycles. It was also stable at −85°C for 50 days. Stability data are presented in Table VI . Stock solution stability was tested and it was found that the maximum storage period for FEB and the IS stock solutions in methanol from first preparation date to preparation date of calibration standards and QC samples is 50 days. FEB is stable in methanol at a nominal temperature of −20°C for 50 days.
Application of the method on real plasma samples
The validated method was applied for the determination of FEB in human plasma following the orally administered single dose of 80 mg to healthy subjects. The mean plasma concentration time curve for three subjects is presented in Figure 4 .
Discussion
The aim of the present work was to determine FEB, using the versatile HPLC technique equipped with the widely available UV detector to attain high sensitivity and selectivity for the detection and quantification of cited drug in human plasma. The aim was also to use a fast and cheap extraction process, allowing the method to be used in the pharmacokinetics evaluation of the drug. The advantages of the suggested HPLC-UV method and the Gide et al. method (16) are their higher sensitivity due to lower LLOQ (0.05 μg/mL), a wide range of temperatures applied in stability studies, utilizing a high-throughput protein precipitation technique that is more rapid than the liquid-liquid extraction technique and finally our method was successfully applied for the analysis of real plasma samples obtained for a bioequivalence study of 80 mg FEB tablet formulations in healthy subjects under a fasting condition.
During the optimization cycle, several chromatographic conditions were attempted using a C18 or C8 column. Various mobile phase compositions of phosphate buffer at different pH values, methanol and acetonitrile, in different proportions were tried in an isocratic mode. We found that pH 3.0 was optimum for separation. Upon switching from phosphate buffer to aqueous phosphoric acid, better sensitivity was obtained. Acetonitrile was better than methanol for better separation of the analytes from matrix peaks and gave a better response. A mobile phase consisting of acetonitrile and 0.5% aqueous phosphoric acid adjusted to pH 3.0 (52 : 48, v/v) was found suitable for the analyte and IS. A reversed-phase column (C18 Bondapack 10 µm, 250 × 4.6 mm, Waters) gave a good peak shape and response even at LLOQ level (0.05 µg/mL). A flow rate of 1.0 mL/min produced suitable separation, peak shape and run time.
A protein precipitation method provides a fast method for sample preparation. Several protein-precipitating agents were tried where acetonitrile gave the best sensitivity and selectivity. The response was consistent even at LLOQ level. Aliquots of the solution were then analyzed by reversed-phase liquid chromatography coupled with ultraviolet detection at 315 nm. Under the suggested conditions, the retention times of FEB and the IS were ∼6.7 and 5.3 min, respectively. The overall run time was 7.5 min.
Conclusion
A rapid, selective and sensitive HPLC/UV assay was developed for the quantitative determination of FEB in human plasma. The developed method is suitable for the routine analysis of FEB in bioequivalence studies due to its simplicity and rapidity. This study reports a highthroughput protein precipitation method for extracting FEB in human plasma and measuring it using the HPLC/UV method. The present method provided excellent selectivity and linearity with an LLOQ of 0.05 µg/mL for FEB. The method was applied for the determination of FEB in human plasma samples for application in bioequivalence study. The pharmacokinetic results will be presented in a future study.
